Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 8 art units • 11 examiners • 0 of 12 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
The Salk Institute for Biological Studies maintains a robust prosecution profile with 12 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 11 distinct examiners and 8 distinct art units. The breadth of art units involved suggests a diverse research portfolio that spans multiple specialized biological and pharmaceutical disciplines, requiring a versatile legal approach to handle various examination styles.
The busiest examiner for the institute is Bretz, Corey Lane, who is currently managing 2 pending office actions. This examiner is the only individual in the data set handling more than a single matter for the organization. The remaining pending office actions are spread among the other distinct examiners, indicating a highly decentralized review process at the patent office that avoids concentration with any single official.
With 12 pending office actions active, the institute's legal strategy must account for the varied requirements of 8 distinct art units. This level of distribution requires coordinating with a large group of 11 distinct examiners, which may lead to differing prosecution timelines across the portfolio. The high ratio of examiners to actions suggests that the institute's current filings are being treated as independent technical inquiries rather than a clustered group of related applications.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (17%) |
| §103 only | 1 (8%) |
| §112 only | 1 (8%) |
| Double-patenting only | 1 (8%) |
| Double-patenting + other | 4 (33%) |
| Multi-statute (no §101) | 3 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRETZ, COREY LANE | 2 | 0.0% | +0.0% |
| MEYER, GEORGE WILLIAM | 1 | 100.0% | +0.0% |
| CHATTERJEE, JAYANTA | 1 | 44.0% | +70.1% |
| GILL, RACHEL B | 1 | 65.4% | +28.8% |
| SHIN, DANA H | 1 | 26.9% | +26.9% |
| LEONARD, ARTHUR S | 1 | 50.5% | +50.4% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.7% |
| KIM, TAEYOON | 1 | 51.4% | +52.2% |
| PRONZATI, GINA | 1 | 65.9% | +48.3% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 47.2% | +63.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17769524 | METHODS FOR MODULATING HUMAN L1 RETROTRANSPOSONS RNA AND COMPOSITIONS FOR USE THEREIN | KIM, TAEYOON | 147d overdue |
| 17637058 | COMPOSITIONS AND METHODS FOR IN VIVO GENE EDITING | LIPPOLIS, ALEXANDRA ROSE | 125d overdue |
| 18954772 | IRON MAN (IMA) OVEREXPRESSION INCREASES DISEASE RESISTANCE | MEYER, GEORGE WILLIAM | — |
| 18840877 | COMPOSITIONS AND METHODS FOR INCREASING PERIDERM IN PLANT ROOTS | CHATTERJEE, JAYANTA | — |
| 18797069 | HSV-1 ONCOLYTIC VIRUS THERAPIES THAT SPECIFICALLY KILL ALT DEPENDENT CANCERS | GILL, RACHEL B | — |
| 18288772 | MULTIPLEX CRISPR/Cas9-MEDIATED TARGET GENE ACTIVATION SYSTEM | SHIN, DANA H | — |
| 18151093 | RECOMBINANT ADENOVIRUS GENOME HAVING A SYNTHETIC TRANSCRIPTIONAL UNIT AND TWO STEP TRANSCRIPTIONAL REGULATION AND AMPLIFICATION | BRETZ, COREY LANE | — |
| 17741311 | COMPOSITIONS AND METHODS FOR HIGH-EFFICIENCY RECOMBINATION OF RNA MOLECULES | BRETZ, COREY LANE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17769524 | METHODS FOR MODULATING HUMAN L1 RETROTRANSPOSONS RNA AND COMPOSITIONS FOR USE THEREIN | KIM, TAEYOON | 147d overdue |
| 17637058 | COMPOSITIONS AND METHODS FOR IN VIVO GENE EDITING | LIPPOLIS, ALEXANDRA ROSE | 125d overdue |
| 18028751 | PATIENT SELECTION BIOMARKERS FOR TREATMENT WITH ULK INHIBITORS | VANHORN, ABIGAIL LOUISE | 19d overdue |
| 18840877 | COMPOSITIONS AND METHODS FOR INCREASING PERIDERM IN PLANT ROOTS | CHATTERJEE, JAYANTA | — |
| 18797069 | HSV-1 ONCOLYTIC VIRUS THERAPIES THAT SPECIFICALLY KILL ALT DEPENDENT CANCERS | GILL, RACHEL B | — |
| 18288772 | MULTIPLEX CRISPR/Cas9-MEDIATED TARGET GENE ACTIVATION SYSTEM | SHIN, DANA H | — |
| 18302962 | SYNTHETIC ADENOVIRUSES TARGETING BONE TISSUE AND USES THEREOF | LEONARD, ARTHUR S | — |
| 17681538 | ADENOVIRAL ASSEMBLY METHOD | PRONZATI, GINA | — |
| Art Unit | Apps |
|---|---|
| 1635 | 3 |
| 1662 | 2 |
| 1631 | 2 |
| 1671 | 1 |
| 1636 | 1 |
| 1633 | 1 |
| 1637 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18954772 | IRON MAN (IMA) OVEREXPRESSION INCREASES DISEASE RESISTANCE | MEYER, GEORGE WILLIAM | 1662 | §103§112 | Non-Final OA | — | Pending | Nov 21, 2024 |
| 18840877 | COMPOSITIONS AND METHODS FOR INCREASING PERIDERM IN PLANT ROOTS | CHATTERJEE, JAYANTA | 1662 | §102§103§112 | Non-Final OA | — | Pending | Aug 22, 2024 |
| 18797069 | HSV-1 ONCOLYTIC VIRUS THERAPIES THAT SPECIFICALLY KILL ALT DEPENDENT CANCERS | GILL, RACHEL B | 1671 | §101§103§112DP | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18288772 | MULTIPLEX CRISPR/Cas9-MEDIATED TARGET GENE ACTIVATION SYSTEM | SHIN, DANA H | 1635 | §103§112DPOther | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18302962 | SYNTHETIC ADENOVIRUSES TARGETING BONE TISSUE AND USES THEREOF | LEONARD, ARTHUR S | 1631 | §112 | Final Rejection | — | Pending | Apr 19, 2023 |
| 18028751 | PATIENT SELECTION BIOMARKERS FOR TREATMENT WITH ULK INHIBITORS | VANHORN, ABIGAIL LOUISE | 1636 | §103DP | Final Rejection | 19d overdue | Pending | Apr 12, 2023 |
| 18151093 | RECOMBINANT ADENOVIRUS GENOME HAVING A SYNTHETIC TRANSCRIPTIONAL UNIT AND TWO STEP TRANSCRIPTIONAL REGULATION AND AMPLIFICATION | BRETZ, COREY LANE | 1635 | §102§103§112DP | Non-Final OA | — | Pending | Jan 06, 2023 |
| 17741311 | COMPOSITIONS AND METHODS FOR HIGH-EFFICIENCY RECOMBINATION OF RNA MOLECULES | BRETZ, COREY LANE | 1635 | §112DP | Non-Final OA | — | Pending | May 10, 2022 |
| 17769524 | METHODS FOR MODULATING HUMAN L1 RETROTRANSPOSONS RNA AND COMPOSITIONS FOR USE THEREIN | KIM, TAEYOON | 1631 | §102§103 | Final Rejection | 147d overdue | Pending | Apr 15, 2022 |
| 17681538 | ADENOVIRAL ASSEMBLY METHOD | PRONZATI, GINA | 1633 | DP | Final Rejection | — | Pending | Feb 25, 2022 |
| 17637058 | COMPOSITIONS AND METHODS FOR IN VIVO GENE EDITING | LIPPOLIS, ALEXANDRA ROSE | 1637 | §101§102§103 | Final Rejection | 125d overdue | Pending | Feb 21, 2022 |
| 18403664 | METHODS OF TREATING NEURODEGENERATIVE DISEASES OR CONDITIONS | PATEL, SAGAR S | 1626 | §103 | Non-Final OA | — | Pending | Jan 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSalk Institute for Biological Studies has 12 pending office actions as of October 2026, spread across 8 art units and 11 examiners.
Corey Lane Bretz has the most, with 2 of Salk Institute for Biological Studies's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
